# US C Reactive Protein Testing Market > US C-Reactive Protein Testing Market Research Report: Size, Share, Trend Analysis By Assay Type (Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assays, Others) and By Applications (Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.62% - **2024:** $ 511.42 Million - **2025:** $ 545.28 Million - **2035:** $ 1,035.43 Million - **Key Players:** Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Beckman Coulter (US), bioMérieux (FR), Quidel Corporation (US) **Report ID:** MRFR/LS/14134-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-c-reactive-protein-testing-market-15661 --- ## Market Summary ## **US C-Reactive Protein Testing Market Overview** As per MRFR analysis, the US C-Reactive Protein Testing Market Size was estimated at 478.95 (USD Million) in 2023. The US C-Reactive Protein Testing Market Industry is expected to grow from 512(USD Million) in 2024 to 1,065.58 (USD Million) by 2035. The US C-Reactive Protein Testing Market CAGR (growth rate) is expected to be around 6.89% during the forecast period (2025 - 2035). ### **Key US C-Reactive Protein Testing Market Trends Highlighted** In the US C-Reactive Protein Testing Market, there is a noticeable trend towards increased awareness of inflammation-related diseases among both healthcare providers and patients. This has been fueled by growing research linking elevated C-Reactive Protein (CRP) levels to conditions such as cardiovascular diseases and autoimmune disorders. The shift towards preventive healthcare is driving demand for CRP testing as a routine assessment tool. Additionally, advancements in diagnostic technology are improving the accuracy and efficiency of CRP tests, making them more accessible in various healthcare settings, including outpatient clinics and at-home testing platforms. Key market drivers include the rise in chronic diseases, which necessitates ongoing monitoring of inflammatory markers. CRP testing serves as an essential component in managing conditions that are prevalent in the US population, such as heart disease, which is a leading cause of death. Furthermore, the healthcare system's movement towards value-based care is pushing healthcare practitioners to adopt testing methods that can provide actionable insights for patient management. Opportunities to be explored include expanding testing capabilities in telemedicine and at-home healthcare, catering to the growing number of patients seeking convenience and efficiency. The pandemic has accelerated the acceptance of remote healthcare, leading to an increase in home testing solutions, including CRP tests. Collaborations between diagnostic companies and digital health platforms can streamline access to these tests and enhance patient engagement. Recent trends also highlight a focus on educational initiatives aimed at both healthcare providers and the public to promote understanding of the importance of CRP levels in health management. By improving education around inflammation and its health implications, there is potential to drive further growth in testing adoption and utilization across the United States. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US C-Reactive Protein Testing Market Drivers** ### **Increasing Prevalence of Inflammatory Diseases** The rise in various inflammatory diseases in the United States has significantly impacted the US C-Reactive Protein Testing Market Industry. According to the Centers for Disease Control and Prevention (CDC), over 50 million Americans are affected by arthritis, a leading cause of inflammation. Also, with more than 27 million adults suffering from osteoarthritis, the demand for C-Reactive Protein testing, which helps assess inflammation, is surging. This spike in inflammatory disease cases is likely to fuel the demand for effective diagnostic tools, which are crucial in managing these conditions, thereby supporting the growth of the C-Reactive Protein testing market. Established organizations such as the American College of Rheumatology and the Arthritis Foundation are promoting awareness and research into these conditions, contributing to increased testing and diagnosis protocols for managing chronic inflammation. ### **Growing Focus on Preventive Healthcare** There is a noticeable shift towards preventive healthcare in the United States, prompting individuals to seek regular health screenings. With a growing emphasis on proactive health measures, the demand for C-Reactive Protein tests is expected to rise, as they serve as an important indicator of inflammation linked with various chronic diseases. According to the National Institute of Health, preventive healthcare can reduce overall healthcare costs by up to 30 percent. Established health organizations are advocating for routine inflammatory marker screenings as part of comprehensive health checks, further driving the growth of the US C-Reactive Protein Testing Market Industry. ### **Advancements in Diagnostic Technology** Technological advancements in diagnostic tools have significantly improved the efficiency and accuracy of C-Reactive Protein Testing in the United States. Innovations such as high-sensitivity assays are now available, enabling more precise measurements of C-Reactive Protein levels. As per the Food and Drug Administration, there has been a notable increase in FDA-approved tests related to C-Reactive Protein. Established entities like the American Association for Clinical Chemistry are continually promoting the integration of advanced technologies in laboratories, paving the way for enhanced testing capabilities.This trend not only meets the growing demand for rapid results but also reinforces the relevance of the US C-Reactive Protein Testing Market Industry in the healthcare sector. ## **US C-Reactive Protein Testing Market Segment Insights** ### **C-Reactive Protein Testing Market Assay Type Insights** The US C-Reactive Protein Testing Market is a critical segment of the healthcare industry, particularly in monitoring inflammation and disease activity in various clinical settings. The Assay Type classification within this market is multifaceted, encompassing various methodologies such as Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), and Immunoturbidimetric Assays, among others. ELISA is highly regarded for its sensitivity and specificity, making it a preferred choice in many laboratories for quantifying C-reactive protein levels, especially in autoimmune diseases and chronic inflammatory states. Its user-friendly procedures and ability to conduct large sample analyses significantly boost its utilization in clinical practices across the US.Chemiluminescence Immunoassay (CLIA) also plays a pivotal role in the market due to its rapid processing time and enhanced detection capabilities. This assay type allows for the swift assessment of CRP levels, making it particularly beneficial in emergency departments and critical care settings where timely diagnosis is crucial for patient outcomes. Additionally, CLIA often shows a lower limit of detection, further solidifying its importance in the monitoring of various diseases.Immunoturbidimetric Assays are gaining traction as they offer a straightforward method for CRP quantification, suitable for integration into automated systems in hospital laboratories. This assay type is ideal for high-throughput environments, thereby improving workflow efficiency, which is a considerable advantage in today's increasingly busy healthcare settings. The "Others" category includes emerging assay technologies that may offer innovative approaches to CRP testing, focusing on enhanced accuracy and ease of use. These alternative methods could address some current limitations faced by traditional assays, potentially leading to increased adoption in clinical and research environments.Overall, the various Assay Type methodologies contribute significantly to the US C-Reactive Protein Testing Market by catering to diverse laboratory needs and conditions. These technologies not only facilitate better patient management but also align with the growing trend of personalized medicine, further driving market opportunities and innovations in CRP assessment. The ongoing advancements and increasing demand for efficient testing methodologies are indicative of a vibrant market landscape, with considerable prospects for growth and enhanced diagnostic precision in patient care. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **C-Reactive Protein Testing Market Application Insights** The Application segment of the US [C-Reactive Protein Testing](../../../reports/c-reactive-protein-testing-market-12157) Market plays a crucial role in diagnosing and managing various inflammatory and autoimmune conditions. C-Reactive Protein testing is pivotal for monitoring diseases such as Diabetes, where inflammation is often a key factor in disease progression. In Rheumatoid Arthritis, this testing aids in assessing disease activity and guiding treatment decisions, highlighting its significance in personalizing care. Additionally, in Cardiovascular Disease, elevated C-Reactive Protein levels can indicate increased risk, making it essential for early intervention strategies.Inflammatory Bowel Disease also benefits from C-Reactive Protein testing, as it helps in monitoring flare-ups and treatment responses. The presence of other conditions in this segment illustrates the broad utility of C-Reactive Protein testing across diverse health issues. The growing awareness of the importance of inflammatory markers and their impact on health outcomes further drives the demand for C-Reactive Protein testing in the United States, establishing it as a vital tool in modern medical practice. ## **US C-Reactive Protein Testing Market Key Players and Competitive Insights** The US C-Reactive Protein Testing Market is characterized by significant competitive dynamics fueled by the increasing prevalence of inflammatory diseases and the growing emphasis on early diagnosis and preventive healthcare. Within this market, key players are actively participating in innovative product development and strategic partnerships to enhance their market positioning. The landscape is shaped by advancements in testing technologies and the rise in demand for high-sensitivity C-reactive protein tests, which serve as crucial markers for inflammatory conditions and cardiovascular risk assessments. Companies are focusing on expanding their product portfolios and improving accessibility to testing services in response to the evolving needs of healthcare providers and patients alike. As competition intensifies, firms in this sector are also leveraging digital tools for data management and reporting to enhance patient outcomes and test accuracy, all while navigating regulatory frameworks. Hologic stands out in the US C-Reactive Protein Testing Market with its strong presence and concentration on women's health, which does synergize with its offerings in the diagnostic space. The company's strengths lie in its robust research and development initiatives, which continually propel the innovation of its diagnostic capabilities. Hologic has developed advanced testing platforms that facilitate rapid and accurate CRP testing, catering to the specific needs of healthcare providers. Furthermore, the company's integration of advanced technologies allows for optimized data management and patient interaction, making its products an integral part of clinical decision-making. Hologic's commitment to quality assurance and its ability to maintain compliance with regulatory requirements are additional factors that reinforce its competitive edge in the market. BioRad Laboratories has established a notable presence in the US [C-Reactive Protein Testing Market](../../../press-release/c-reactive-protein-testing-market), primarily through its extensive portfolio of diagnostic solutions and laboratory instruments. The company offers a variety of key products related to C-reactive protein testing that have gained traction across healthcare settings due to their reliability and accuracy. BioRad Laboratories' strengths are derived from its expansive distribution network and established customer relationships, coupled with strategic collaborations that enable access to the latest technological advancements. The company's focus on innovation is complemented by imperative mergers and acquisitions aimed at enhancing its overall market offerings and expanding its capabilities within the diagnostics space. With a strong commitment to supporting clinical laboratories, BioRad Laboratories remains dedicated to providing healthcare professionals with solutions that improve patient care and streamline operational efficiencies. ### **Key Companies in the US C-Reactive Protein Testing Market Include** ## **US C-Reactive Protein Testing Market Industry Developments** Recent developments in the US C-Reactive Protein Testing Market have seen increased demand for rapid diagnostic tests, especially in the wake of heightened health awareness post-pandemic. Companies like Hologic and Roche Holding are witnessing growth driven by advancements in their testing technologies. Collaborative efforts between firms such as Abbott Laboratories and Quest Diagnostics are enhancing the precision and accessibility of testing, thereby propelling market expansion. Merger and acquisition activities in this space remain significant, with notable transactions including the acquisition of Hemosure by Siemens Healthineers in September 2023, aimed at strengthening their diagnostic portfolio, which has been widely covered by media outlets. In prior years, Labcorp expanded its testing capabilities with the acquisition of Genova Diagnostics in March 2022, bolstering their portfolio in inflammatory markers testing. The overall valuation of the market has surged, influenced by an increasing focus on early detection of diseases linked to inflammation, which C-Reactive Protein testing supports. This surge emphasizes the strategic movements within the market, particularly the collaborations and technological innovations being pursued by these key players, providing a vibrant landscape in the US C-Reactive Protein Testing Market. ## **US C-Reactive Protein Testing Market Segmentation Insights** ### **C-Reactive Protein Testing Market Assay Type Outlook** ### **C-Reactive Protein Testing Market Application Outlook** ## Market Drivers ### Rising Incidence of Chronic Diseases The increasing prevalence of chronic diseases such as cardiovascular disorders and diabetes in the US is a primary driver for the c reactive-protein-testing market. Chronic inflammation is often a key factor in these conditions, leading healthcare providers to utilize C-reactive protein testing as a diagnostic tool. According to recent data, nearly 60% of adults in the US are living with at least one chronic condition, which underscores the necessity for effective monitoring and management strategies. This trend is likely to propel the demand for CRP testing, as it aids in assessing inflammation levels and guiding treatment decisions. Consequently, the c reactive-protein-testing market is expected to experience substantial growth as healthcare systems increasingly prioritize early detection and preventive measures. ### Increased Focus on Personalized Medicine The growing emphasis on personalized medicine is influencing the c reactive-protein-testing market in the US. As healthcare shifts towards tailored treatment approaches, CRP testing is being recognized for its potential to provide valuable insights into individual patient profiles. By assessing inflammation levels, healthcare providers can better understand a patient's unique health status and customize treatment plans accordingly. This trend aligns with the broader movement towards precision medicine, which aims to optimize patient outcomes through targeted therapies. As personalized medicine continues to gain traction, the demand for CRP testing is expected to rise, further propelling the growth of the c reactive-protein-testing market. ### Growing Awareness of Inflammatory Diseases There is a notable increase in public and professional awareness regarding inflammatory diseases, which is significantly impacting the c reactive-protein-testing market. Educational campaigns and research publications have highlighted the role of inflammation in various health issues, prompting both patients and healthcare providers to seek CRP testing as a valuable diagnostic tool. This heightened awareness is reflected in the rising number of tests conducted annually, with estimates suggesting a growth rate of approximately 8% in testing frequency over the next few years. As individuals become more informed about the implications of inflammation on their health, the demand for CRP testing is likely to rise, further driving the market's expansion. ### Technological Innovations in Testing Methods Technological advancements in testing methodologies are playing a crucial role in shaping the c reactive-protein-testing market. Innovations such as point-of-care testing devices and automated laboratory systems are enhancing the efficiency and accuracy of CRP testing. These advancements not only reduce the time required for test results but also improve accessibility for patients in various healthcare settings. The market is likely to benefit from these innovations, as they facilitate quicker diagnosis and treatment decisions. Furthermore, the introduction of more sensitive and specific testing kits is expected to attract healthcare providers, thereby driving the overall growth of the c reactive-protein-testing market. ### Integration of CRP Testing in Routine Check-ups The integration of C-reactive protein testing into routine health check-ups is emerging as a significant driver for the c reactive-protein-testing market. Healthcare providers are increasingly recognizing the importance of assessing inflammation levels as part of comprehensive health evaluations. This trend is supported by clinical guidelines that recommend CRP testing for patients with risk factors for cardiovascular diseases. As a result, the market is witnessing a shift towards preventive healthcare, with CRP testing becoming a standard component of patient assessments. This shift is expected to enhance the market's growth trajectory, as more individuals undergo routine testing, thereby increasing the overall demand for CRP testing services. ## Future Outlook The [C Reactive Protein Testing Market](https://www.marketresearchfuture.com/reports/c-reactive-protein-testing-market-12157) is projected to grow at a 6.62% CAGR from 2025 to 2035, driven by increasing chronic disease prevalence and advancements in diagnostic technologies. **New opportunities:** - Development of portable CRP testing devices for home use. Integration of AI analytics in CRP testing for personalized medicine. Expansion of CRP testing services in telehealth platforms. By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare demands. ## Segment Insights ### By Assay Type: ELISA (Largest) vs. CLIA (Fastest-Growing) Among the assay types in the US c reactive-protein-testing market, Enzyme-linked immunosorbent assay (ELISA) holds the largest share, driven by its established use in laboratories and clinics for accurate and reliable testing. Chemiluminescence Immunoassay (CLIA), while not as widely adopted as ELISA, is gaining traction due to its higher sensitivity and faster results, positioning it as a key player in the emerging segments. The growth trends indicate a shift towards more automated and high-throughput methods, particularly with CLIA technology, which caters to the increasing demand for efficiency in diagnostic processes. Furthermore, advancements in immunoassay technologies and rising chronic disease prevalence are propelling the market forward, making it essential for laboratories to adopt modern testing methodologies to enhance patient outcomes. ELISA (Dominant) vs. CLIA (Emerging) ELISA is currently the dominant assay type in the US c reactive-protein-testing market, thanks to its cost-effectiveness and reliability. It is frequently utilized in clinical settings for various diagnostic purposes, particularly in detecting inflammation markers like C-reactive protein. In contrast, Chemiluminescence Immunoassay (CLIA) is emerging rapidly, characterized by its high sensitivity and the ability to process multiple samples quickly. This growth is largely attributed to technological advancements that are enhancing CLIA capabilities, making it an attractive option for laboratories aiming for higher throughput and faster turnaround times, thus tapping into the increasing demand for rapid diagnostic solutions. ### By Application: Cardiovascular Disease (Largest) vs. Diabetes (Fastest-Growing) In the US c reactive-protein-testing market, the distribution of market share among application segments reveals that Cardiovascular Disease represents the largest segment due to its significant prevalence and the rising awareness of heart health. This segment benefits from extensive research and advancements in testing technologies that enhance diagnostic accuracy. In contrast, Diabetes, while smaller in share, is rapidly gaining prominence as awareness and diagnosis of the condition are increasing. The increased outreach for preventive care and management strategies has positively impacted this segment's performance. Growth trends in the US c reactive-protein-testing market indicate a shift towards a more proactive approach in healthcare. The demand for C-reactive protein tests is being driven by the rising incidences of Chronic Diseases, especially among the aging population. Additionally, innovations in testing methodologies and the emphasis on early diagnosis are propelling segments like Diabetes as it becomes increasingly recognized as a critical health concern. Investment in healthcare services aimed at managing these conditions is likely to provide a further boost to the market. Cardiovascular Disease: Largest vs. Diabetes: Emerging Cardiovascular Disease is the dominant segment in the US c reactive-protein-testing market, attributed to the high incidence of heart-related issues. Its characteristics include a robust infrastructure for detecting inflammation, and strong clinical guidelines supporting the use of C-reactive protein tests for risk assessment. Meanwhile, [Diabetes](../../../reports/diabetes-market-2966) is emerging as a segment on the rise, driven by increasing diagnosis rates and heightened public awareness. Significant focus on diabetes management programs and advancements in testing technologies are transforming this segment into a key component of healthcare strategies. The comparative position indicates that while Cardiovascular Disease remains foundational in the market, Diabetes is set to capture more attention and investment in the coming years. ## Competitive Benchmarking The c reactive-protein-testing market is currently characterized by a dynamic competitive landscape, driven by increasing demand for rapid and accurate diagnostic tools. Key players are focusing on innovation and strategic partnerships to enhance their market presence. Companies such as Roche Diagnostics (CH), Abbott Laboratories (US), and Thermo Fisher Scientific (US) are at the forefront, leveraging advanced technologies and expanding their product portfolios to meet the evolving needs of healthcare providers. Their collective strategies not only foster competition but also contribute to the overall growth of the market, as they strive to deliver high-quality testing solutions that align with clinical requirements. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive innovation. This competitive environment encourages smaller firms to adopt niche strategies or seek collaborations to remain relevant. In October 2025, Abbott Laboratories (US) announced the launch of a new high-sensitivity C-reactive protein test, which is expected to significantly improve the detection of inflammation-related conditions. This strategic move underscores Abbott's commitment to innovation and positions the company to capture a larger share of the market by addressing the growing demand for precise diagnostic tools. The introduction of this test may enhance patient outcomes and solidify Abbott's reputation as a leader in the diagnostics sector. In September 2025, Roche Diagnostics (CH) expanded its partnership with a leading telehealth provider to integrate its C-reactive protein testing into remote patient monitoring systems. This initiative reflects Roche's strategic focus on digital transformation and highlights the increasing importance of telehealth solutions in the diagnostics landscape. By facilitating remote access to testing, Roche aims to enhance patient engagement and streamline healthcare delivery, potentially leading to improved health outcomes. In August 2025, Thermo Fisher Scientific (US) acquired a biotechnology firm specializing in point-of-care testing technologies. This acquisition is likely to bolster Thermo Fisher's capabilities in the C-reactive protein-testing segment, enabling the company to offer more comprehensive solutions. The strategic importance of this move lies in Thermo Fisher's ability to leverage the acquired technology to enhance its product offerings and expand its market reach, thereby reinforcing its competitive position. As of November 2025, current trends in the c reactive-protein-testing market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are increasingly shaping the competitive landscape, as companies collaborate to enhance their technological capabilities and market reach. Looking ahead, it appears that competitive differentiation will evolve, with a shift from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition may redefine how companies position themselves in the market, emphasizing the importance of delivering value through advanced diagnostic solutions. ## Recent News & Developments Recent developments in the US C-Reactive Protein Testing Market have seen increased demand for rapid diagnostic tests, especially in the wake of heightened health awareness post-pandemic. Companies like Hologic and Roche Holding are witnessing growth driven by advancements in their testing technologies. Collaborative efforts between firms such as Abbott Laboratories and Quest Diagnostics are enhancing the precision and accessibility of testing, thereby propelling market expansion. Merger and acquisition activities in this space remain significant, with notable transactions including the acquisition of Hemosure by Siemens Healthineers in September 2023, aimed at strengthening their diagnostic portfolio, which has been widely covered by media outlets. In prior years, Labcorp expanded its testing capabilities with the acquisition of Genova Diagnostics in March 2022, bolstering their portfolio in inflammatory markers testing. The overall valuation of the market has surged, influenced by an increasing focus on early detection of diseases linked to inflammation, which C-Reactive Protein testing supports. This surge emphasizes the strategic movements within the market, particularly the collaborations and technological innovations being pursued by these key players, providing a vibrant landscape in the US C-Reactive Protein Testing Market. ## Report Scope | MARKET SIZE 2024 | 511.42(USD Million) | | --- | --- | | MARKET SIZE 2025 | 545.28(USD Million) | | MARKET SIZE 2035 | 1035.43(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.62% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Beckman Coulter (US), bioMérieux (FR), Quidel Corporation (US) | | Segments Covered | Assay Type, Application | | Key Market Opportunities | Integration of advanced diagnostic technologies enhances accuracy in the c reactive-protein-testing market. | | Key Market Dynamics | Rising demand for rapid diagnostic tools drives innovation in c reactive-protein testing methodologies and technologies. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US c reactive-protein-testing market in 2024?** A: The market valuation was $511.42 Million in 2024. **Q: What is the projected market valuation for the US c reactive-protein-testing market by 2035?** A: The projected valuation for 2035 is $1,035.43 Million. **Q: What is the expected CAGR for the US c reactive-protein-testing market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 6.62%. **Q: Which assay type had the highest valuation in the US c reactive-protein-testing market in 2024?** A: Chemiluminescence Immunoassay (CLIA) had the highest valuation at $150.0 Million in 2024. **Q: What is the projected valuation for the Immunoturbidimetric assays segment by 2035?** A: The projected valuation for Immunoturbidimetric assays is expected to reach $150.0 Million by 2035. **Q: Which application segment is anticipated to show significant growth in the US c reactive-protein-testing market?** A: The Cardiovascular Disease application segment is anticipated to grow significantly, with a valuation of $306.84 Million by 2035. **Q: Who are the key players in the US c reactive-protein-testing market?** A: Key players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific. **Q: What was the valuation of the Diabetes application segment in 2024?** A: The valuation of the Diabetes application segment was $51.14 Million in 2024. **Q: What is the expected growth for the Others segment in the Assay Type category by 2035?** A: The Others segment in the Assay Type category is expected to grow to $385.43 Million by 2035. **Q: How does the market valuation in 2035 compare to that in 2024?** A: The market valuation in 2035 is projected to be approximately double that of 2024, increasing from $511.42 Million to $1,035.43 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-c-reactive-protein-testing-market-15661*